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Patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are prone 
to present with antibody production deficits associated with recurrent or severe bacterial 
infections that might benefit from human immunoglobulin (Ig) (IVIg/SCIg) replacement 
therapy. However, the original IVIg trial data were done before modern therapies were 
available, and the current indications do not take into account the shift in the immune 
situation of current treatment combinations and changes in the spectrum of infections. 
Besides, patients affected by other B cell malignancies present with similar immunode-
ficiency and manifestations while they are not covered by the current IVIg indications. 
A potential beneficial strategy could be to vaccinate patients at monoclonal B lympho-
cytosis and monoclonal gammopathy of undetermined significance stages (for CLL and 
MM, respectively) or at B-cell malignancy diagnosis, when better antibody responses are 
attained. We have to re-emphasize the need for assessing and monitoring specific anti-
body responses; these are warranted to select adequately those patients for whom early 
intervention with prophylactic anti-infective therapy and/or IVIg is preferred. This review 
provides an overview of the current scenario, with a focus on prevention of infection in 
patients with hematological malignancies and the role of Ig replacement therapy.
Keywords: antibody production defect, hypogammaglobulinemia, chronic lymphocytic leukemia, hematological 
malignancy, multiple myeloma, replacement immunoglobulins
iNTRODUCTiON
Patients affected by hematological malignancy, in particular chronic lymphocytic leukemia (CLL) 
and multiple myeloma (MM), were recognized as presenting antibody production deficits many 
years ago (1, 2), and the proposal was made that they might benefit from antibody replacement 
therapy (3). Landmark clinical trials in CLL and MM in the late 1980s and early 1990s settled the 
basis for the current indications of intravenous immunoglobulins (IVIg) in hematological malig-
nancies associated with severe secondary hypogammaglobulinemia and recurrent infections (4–6). 
In recent years, the convergence of better immunological evaluation of antibody responses for 
the selection of patients who might benefit from immunoglobulin replacement therapy, together 
with substantially improved therapies for these malignant conditions that lengthen survival, 
has prompted the need to review the role of IVIg (or subcutaneous administration, SCIg) in the 
TABLe 1 | Clinical trials to determine effectiveness and dosage of replacement intravenous immunoglobulin in hematological malignancy [adapted from 
Dhalla et al. (9)].
Publication Target population Study description Relevant results
Cooperative 
Group (4)
CLL patients (81) with 
hypogammaglobulinemia or 
serious infections
Multicenter controlled, randomized double-blind, IVIg 
400 mg/kg/21 days versus placebo for 12 months
Fewer major and moderate bacterial infections overall
Longer period to first serious bacterial infection
No differences in viral and fungal infections
Griffiths 
et al. (29)
CLL (8) and low grade 
NHL (4) patients with 
hypogammaglobulinemia or 
serious infections
Double-blind, randomized crossover IVIg 400 mg/
kg/21 days versus placebo for 12 months then 
changed to the alternative drug
Fewer major and moderate bacterial infections overall
Serious bacterial infection showed a growing trend with 
IgG < 6.4 g/L
No differences in trivial infections
Chapel et al. 
(31)
MM patients (83) with 
hypogammaglobulinemia or 
infections
Double-blind, randomized IVIg 400 mg/kg/21 days 
versus placebo
Fewer life-threatening and severe and recurrent infections
Maximum benefit in patients with poor pneumococcal 
response
Chapel et al. 
(5)
CLL patients (34) with 
hypogammaglobulinemia and 
infections
Double-blind, randomized IVIg at either 500 or 
250 mg/kg/28 days
Similar rates of infection
Jurlander 
et al. (32)
CLL patients (15) with 
hypogammaglobulinemia and 
recurrent infections
Open label IVIg 1,000 mg/21 days Fewer hospital admissions and febrile episodes
No difference in severe infections
No difference in antibiotic prescription
Sklenar et al. 
(30)
CLL (31) and MM (31) patients Multicentre double-blind, randomized parallel-group 
IVIg at 100, 400, and 800 mg/kg/21 days
Optimal dose was 400 mg/kg for prevention of bacterial 
infections and for increasing pneumococcal antibody 
levels
Boughton 
et al. (6)
CLL patients (42) with 
hypogammaglobulinemia and 
infections
Randomized parallel-group IVIg 18 g/21 days versus 
placebo and switched to 24 g versus 18 g if ≥3 
infections
Fewer serious and moderate bacterial infections
50% who required dose increase subsequently 
infection free
Majority of infections associated with IgG < 3 g/L
CLL, chronic lymphocytic leukemia; MM, multiple myeloma; NHL, non-Hodgkin lymphoma.
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prevention of infectious complications. Besides, there are other 
B cell malignancies with similar immune defects that are not 
currently authorized as indications for IVIg, thus resulting in 
subsequent discrimination of such patients.
Outline of Article
First, we briefly review the current evidence for the immunologi-
cal approach to the prevention of infectious complications associ-
ated with defective antibody responses in CLL and MM. We then 
survey the current challenges derived from the improvements in 
diagnosis and therapy of hematological malignancies and discuss 
some practical issues. Finally, we consider the potential indices 
for better selection of patients most likely to benefit from early 
intervention with IVIg or SCIg.
CURReNT eviDeNCe-BASeD 
GUiDeLiNeS FOR iMMUNOGLOBULiN 
THeRAPY iN HeMATOLOGiCAL 
MALiGNANCieS
Recurrent or severe infections are a major cause of morbidity and 
mortality in patients with CLL (between 30 and 50% of deaths) 
(7–9) and MM (22% of deaths in the first year after diagnosis) 
(10), especially in patients with renal failure (11).
Hypogammaglobulinemia (low serum levels of IgG and IgA 
with variable IgM) is a well-recognized complication associated 
with hematological malignancy, most commonly in CLL and 
MM, while not common at diagnosis and during the natural his-
tory of other B cell malignancies (12). It is present in about a 25% 
of patients at diagnosis and up to 85% during the disease course, 
rendering them susceptible to infections (7, 9, 13, 14). It occurs 
in patients with mutated and unmutated immunoglobulin heavy 
chain (IGHV) genes (7). Nevertheless, other immune defects are 
present in these patients mostly due to the underlying disease and 
to chemotherapeutic protocols, namely neutropenia, mucosal 
lesions, T-lymphocyte dysregulation and altered cytokine secre-
tion profiles, complement activation (15–17), NK cell dysfunc-
tion (18), phagocytic alterations (19, 20), as well as the elderly 
age of such patients and their poor functional status (7, 21–23).
Complex causes of these low immunoglobulin levels (Igs) 
include defective production of polyclonal Igs due to abnormal 
function of non-clonal CD5− B cells; impaired IgG and IgA 
class-switch through abnormal CD40–CD40L interaction and 
down-modulation of CD40L (24, 25); impaired help and exces-
sive suppression by T-cells (26, 27); sequestration of T-cell help by 
CLL cells in pseudofolicles (7), inhibition of CD95+ plasma cells 
in the bone marrow via interaction with CD95L on CLL B-cells 
(28), and iatrogenic myelosuppressive chemotherapy (9, 21).
Data from six randomized clinical trials in CLL and one 
with MM patients with hypogammaglobulinemia and history of 
infections demonstrated that IVIg significantly decreased the rate 
of bacterial infections and prolonged the time to first infection, 
with no differences in non-bacterial infections (Table 1). These 
trials suggested that the best dosing was 400 mg/kg/3 weeks until 
steady state is reached, followed by 400  mg/kg/5  weeks (grade 
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A recommendation, level 1b evidence) (4–6, 29–33). Although 
infections are a major cause of morbidity and mortality in CLL, 
neither survival benefit nor improvement in quality of life could 
be demonstrated, which is not surprising given the follow-up 
period of 1 year (4, 34). A recent 14-year retrospective study in 
a large series of CLL patients confirmed that hypogammaglobu-
linemia does not appear to impact overall survival (14). Based 
on the results of the first controlled trial in a wide range of CLL 
patients, IVIg was not cost-effective (35). In patients with MM, 
IVIg for 6–12 months reduced the risk of severe infectious com-
plications (grade A recommendation, level 1b evidence) (31). As 
a result, IVIg is currently reserved for selected CLL patients with 
hypogammaglobulinemia and recurrent bacterial infections, 
especially those in whom prophylactic antibiotics have failed, or 
with severe infections requiring IV antibiotics or hospitalization 
and serum IgG levels <400 mg/dL (grade 2B recommendation, 
level 1A of evidence). Following the original trial, IVIg may be 
recommended for plateau phase MM patients with hypogamma-
globulinemia and recurrent bacterial infections who have failed 
to respond to pneumococcal immunization (36, 37).
However, most of the trial data on which these recommenda-
tions are based is over 20 years old. The spectrum of infections has 
changed in the last decade. Encapsulated bacteria (Streptococcus 
pneumoniae, Staphylococcus aureus, and Haemophilus influenzae) 
and herpesviruses remain the most prevalent cause of infections 
in CLL patients, mainly of the respiratory tract but also the skin, 
urinary and gastrointestinal tracts, and bloodstream (9, 38, 39). 
Additional pathogens of concern vary depending upon the treat-
ment regimen (discussed below).
The original IVIg trial data were done before modern therapies 
were available. The current guidelines do not take into account 
the shift in the immune situation of current treatment combina-
tions (40). On the other hand, the above treatment studies were 
performed without specific antibody testing for patient selection. 
The use of similar chemotherapeutical protocols in other lym-
phoproliferative syndromes, mainly indolent non-Hodgkin lym-
phomas (iNHL) (41, 42), suggests that there may be low serum 
Igs in these patients not previously included in trials (43). This 
leaves a number of patients without access to IVIg. Regarding 
MM, although a profound antibody deficit may occur before the 
plateau phase, and the risk of fungal and viral infections is highest 
during the first 3 months after diagnosis and therapy, there have 
been no new trials of infection prevention with IVIg (37). In view 
of the above, there is a need to re-assess both the level of antibody 
failure and the role of IVIg on the basis of earlier diagnosis and 
newer treatment modalities.
SPeCiFiC ANTiBODY PRODUCTiON 
ReSPONSeS iN CLL/MM: 
iMMUNOLOGiCAL evALUATiON AND 
MONiTORiNG
Specific Antibody Responses in B-Cell 
Malignancies
Not all patients with hypogammaglobulinemia present with 
infectious complications, so a poor response to pneumococcus 
was suggested as a good predictor of infections (13, 31); further-
more, serious infections can occur in the absence of hypogamma-
globulinemia due to other reasons such as neutropenia or T cell 
suppression. Low baseline levels of specific exposure antibodies 
against various bacterial, viral, fungal, and protozoan pathogens 
have been described in these disorders (44). B-cell antimicrobial 
dysfunction increases progressively from monoclonal gammopa-
thy of undetermined significance (MGUS) to Waldenstrom mac-
roglobulinemia to MM (31, 44). In therapy-naive CLL patients, 
seroconversion from positive to negative IgG values was noted for 
EBV- (3.6%) and, most frequently, for VZV-specific IgG (18%), 
while IgG specific for CMV was preserved (45). Significantly, 
lower responses to vaccination in CLL patients with respect to 
healthy subjects have been reported against diverse antigens. 
Specific antibody production to polysaccharide antigens (T-cell-
independent response), such as classical 23-valent pneumococcal 
vaccine (PPV23), is markedly impaired in these patients (13, 31, 
46). Defective response to protein antigens, such as tetanus toxoid 
and influenza virus, is also apparent (47, 48). Interpretation of 
vaccine responses is complex and requires diverse clinical consid-
erations (49). For the evaluation of primary responses, an increase 
greater than threefold after 4 weeks with respect to prevaccination 
levels is considered normal (49). The use of Salmonella typhi Vi 
vaccine (50) with pure polysaccharide extract may add clinical 
value in this population.
immunological evaluation in B-Cell 
Malignancy
To evaluate the role of immunological deficiencies and to moni-
tor patients with hematological malignancy, a complete clinical 
history of infections is recommended at diagnosis and during 
follow-up, as well as quantification of serum immunoglobulins 
(51) and circulating lymphocyte subsets, including CD4 and CD8 
T cells as well as B cells (provided the B cell count in CLL is not 
excessively high) (Table  2). Neutrophil counts should be also 
regularly monitored.
A recent review by Dhalla et al. (9) has highlighted the relevant 
role of routine immunological evaluation for secondary specific 
antibody deficiency to protein and polysaccharide immuniza-
tions in CLL as a method for predicting patients prone to infec-
tions. These responses should be monitored every 6–12 months 
and after significant bacterial infections or immunosuppressive 
therapy, and this approach could be extended to other hemato-
logical malignancies.
IgG subclass evaluation could be useful. In a large series of CLL 
patients, subclass deficiency (particularly IgG3 and IgG1 subclass 
deficiency) better correlated with recurrent or significant infec-
tions than hypogammaglobulinemia itself (100% of IgG subclass 
deficiency versus 50% of hypogammaglobulinemia, respectively) 
(52). In another study, decreased concentrations of IgG4 and 
IgG2 were associated with increased susceptibility to infection 
(17). However, other studies have not shown association between 
IgG subclass deficiency and infection in CLL (53).
A recent study showed more serious infections in secondary 
than in primary antibody deficiency patients and similar diag-
nostic delay and incidence of bronchiectasis (54). For early detec-
tion of preventable lung involvement, pulmonary function tests 
TABLe 2 | initial proposed immunological evaluation in patients with 
hematological malignancy.
Mandatory
Detailed medical history. History of recurrent or unusual infections, family 
history
Complete physical examination, including the skin, all mucous membranes, 
lymph nodes, spleen, and rectum
CBC with manual differential (presence of anemia, neutropenia, lymphopenia, 
and thrombocytopenia)
Quantitative IgG, IgA, IgM, and IgE levels
Highly recommended tests
Isohemagglutinin titers
IgG antibody titers to prior immunizations/exposure
Antibody response to vaccine antigens (e.g., non-conjugated and conjugated 
pneumococcal, tetanus, diphtheria, S. typhi, meningococcal antigens, 
Haemophilus influenzae b)
T and B cell subsets immunophenotyping and absolute counts
Additional tests
Lung function tests
Thoracic CT
Memory B cell phenotype
Autoantibodies in autoimmune phenomena: antinuclear, anti-DNA, 
antiphospholipid, anti-platelet and anti-neutrophil antibodies, cold agglutinins
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and high-resolution computerized lung tomography are essential 
to prevent development and/or progression of bronchiectasis 
(9). Our strong recommendation is to always consult a clinical 
immunologist for performing immunological evaluation.
DiAGNOSiS AND THeRAPY iSSUeS 
CHALLeNGiNG THe ROLe OF 
PReveNTiON wiTH iNTRAveNOUS/
SUBCUTANeOUS GAMMAGLOBULiNS
Authorized indications may not be aligned with the current clini-
cal scenario, which stems from diagnostic and therapy changes in 
hematological malignancies in recent years.
The 2008 revised WHO Classification of Tumours of 
Haematopoietic and Lymphoid Tissues (55) adopted consensus 
guidelines for the definition of some well-established diseases, 
including CLL and MM under the common denomination of 
mature B-cell neoplasms with other entities. According to this 
classification, CLL and small lymphocytic lymphoma (SLL) are 
recognized as different manifestations of a single disease entity 
(56). Some patients may present solely with lymphadenopathy, 
organomegaly, and presence of infiltrating monoclonal B cells 
with the same immunophenotype as CLL cells, but lacking 
peripheral blood lymphocytosis (57). Moreover, CLL patients are 
currently being diagnosed earlier in life than was previously the 
case and the distinction of monoclonal B lymphocytosis (MBL) 
from CLL is based on practice guidelines of 5,000  lymphocyte 
counts/μL, as no proven biological parameter can distinguish 
MBL from CLL or identify which patients will progress to 
clinically significant disease more rapidly (58, 59). It appears 
that the prevalence of cases that present as “SLL” may be much 
lower than that of CLL (60). CLL is classified separately as SLL in 
the International Classification of Diseases (ICD)-10-CM 2015 
system (ICD-10).
In the revised 2008 classification, there were no recommen-
dations for changing the definition of recognized categories of 
MGUS, and regrouped the continuum of smoldering myeloma 
and indolent myeloma in asymptomatic myeloma. The presence 
of radiographically detected bone lesions, even if not sympto-
matic, would exclude a patient from this category, because these 
are an indication for treatment (55, 56). To widen the scope of 
IVIg use and to favor access for other B-cell malignant neoplasms, 
the Canadian guidelines of IVIg use in secondary immunode-
ficiencies established the indication as infection prophylaxis 
in adults with “malignant hematological disorders” associated 
with secondary hypogammaglobulinemia and either a recent 
life-threatening infection, which is thought to be caused by low 
levels of polyclonal Ig or recurrent episodes of clinically sig-
nificant infections necessitating the use of antibiotics and which 
are reasonably thought to be caused by low levels of polyclonal 
immunoglobulins (23).
emerging infections with Novel Therapies
Current front-line treatment strategies for CLL including com-
bination chemotherapy and biologic agents, such as fludarabine 
plus cyclophosphamide plus Rtx (FCR) or bendamustine plus Rtx 
(BR) or alemtuzumab, have greatly improved overall survival, 
complete response rate and progression-free survival (61–65). 
However, it has been suggested that these combination regimens 
increase synergistically myelosuppression and immunosuppres-
sion, which comes to the prize of an increased risk of infections 
(66, 67). Severe or unusual infections, with higher rates of global 
infections compared with the historical group of patients treated 
with FC alone but without significant influence in infection-related 
mortality have been reported (62). Particularly, the growing use 
of Rtx in front-line combination chemotherapy with fludarabine 
(FCR) increases the risk of all types of infections with respect to 
Rtx in combination with cyclophosphamide, doxorubicin, vin-
cristine, and prednisone (R-CHOP) or with cyclophosphamide, 
vincristine, and prednisone (R-CVP) chemotherapy (68). FCR 
regimen results in a significant myelosuppression and high rates 
of early and late infections, especially in elderly patients (61). 
With respect to maintenance therapy, Rtx alone for 2 years after 
induction therapy was associated with higher rate of all types 
of infections than the observation alone group (66 versus 50%) 
without influence in infection-related mortality (69). Anti-CD20 
monoclonal antibodies have been associated with CMV infec-
tions and other virus reactivations (hepatitis B and polyomavirus 
JC) (63, 70, 71). Reactivation of herpes viruses have also been 
described related to treatment with purine analogs (as Flu) and 
alemtuzumab (8). With FR combination but also alemtuzumab, 
opportunistic infections by Pneumocystis, Listeria, mycobacteria, 
and Candida have become a real concern and occur frequently 
during the first 3  months of therapy and in previously treated 
patients (7, 72–74). Second- and third-generation anti-CD20 
monoclonal antibodies are humanized or fully human antibodies 
used in CLL and indolent NHL with either higher complement-
dependent cytotoxicity or antibody-dependent cell-mediated 
cytotoxicity or direct cytotoxic effects than Rtx (75), but their 
infections profile in the long-term respect to that of Rtx remain 
to be explored. Obinutuzumab use for hematological malignancy 
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was associated with severe infection in 7% of patients in a recent 
clinical trial (76).
The impact of new biologicals for hematological malignan-
cies that inhibit B-cell receptor (BCR) signaling pathway, B cell 
leukemia/lymphoma-2 (Bcl-2) antagonists, and chimeric antigen 
receptor (CAR) T cells in terms of long-term infectious complica-
tions has not been established. BCR inhibitors’ approved to date 
include the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib; 
the selective inhibitor of the phosphatidylinositol 3-kinase (PI3K) 
delta isoform idelalisib; as well as Syk inhibitor fostamatinib 
disodium (FosD) and SRC family kinases inhibitors (dasatynib, 
bafetinib). A recent study reports ibrutinib to have a better impact 
on humoral reconstitution and hence lower infection rates at 
12  months (77). However, in a large multicenter, open-label, 
clinical trial evaluating ibrutinib versus anti-CD20 (ofatumumab) 
therapy in refractory CLL, severe infections (mainly pneumonia, 
urinary tract infections, and pyrexia) were similar in both groups 
(24 versus 22% of patients), with higher infections in general 
in the ibrutinib group (70 versus 54%, respectively), although 
patients on ibrutinib had longer drug exposure (median, 8.6 
versus 5.3 months) and more than 3 months longer adverse event 
reporting period (78). The rate of severe infections was lower 
when ibrutinib was given as first-line therapy (4% pneumonia and 
4% diarrhea) (79). In the clinical trial with idelalisib for refractory 
CLL reported infections included pneumonia in 6% and febrile 
neutropenia in 5% (80); another clinical trial with idelalisib for 
indolent refractory NHL included severe neutropenia in 27% and 
pneumonia in 7% (81), while a clinical trial on treatment-naive 
CLL patients reported 18% incidence of pneumonia (82). Bcl-2 
antagonists, such as venetoclax, have shown in a recent phase II 
clinical trial in refractory CLL an incidence of pneumonia in 6% 
and febrile neutropenia in 5% of patients (83). In summary, despite 
promising clinical efficacy and acceptable adverse effects’ profiles, 
these later agents inhibit key molecules in B cell activation and 
differentiation and also other relevant pathways independent of 
BCR and neutrophils. Thus, the real clinical extent of the humoral 
and cellular immune and innate defect of these new agents at the 
long term, as shown by the primary defects of these molecules 
(84, 85) remains to be determined.
On the other hand, CD19 CAR T cells have been used in 
relapsed and high-risk CLL with overall response rate of 57% of 
14 patients and persistent B cell aplasia in 100% of patients with 
complete remission (CR) and half of the patients with partial 
remission (86, 87). One out of the 4 patients who achieved CR 
died of an infectious surgery complication almost 2 years after 
CAR T therapy. Severe hypogammaglobulinemia in these patients 
was managed with IVIg (86). Interestingly, long-lived plasma cells 
may account for the persistence of secondary responses to previ-
ous exposures (88).
Similar front-line treatment regimens as for CLL (mostly FluR 
combination) and novel biologic agents are being used in iNHL, 
mostly in the management of follicular lymphoma (FL), mantle-
cell lymphoma (MCL), and cases of diffuse large cell lymphoma 
(DLCL), leading to substantial improvement in prognosis and 
overall survival (89–92).
The issue of immune hyporesponsiveness during specific 
intensive chemotherapy is still unexplored. Secondary antibody 
responses do not seem to be invariably impaired after anti-CD20 
monoclonal antibodies, but primary responses, as tested in 
numerous immunization studies, are clearly impaired (93, 94). 
Rtx has been associated with prolonged hypogammaglobulinemia 
(95, 96) and with neutropenia (even with delayed-onset) (97), 
although difficult to quantify due to confounding factors, namely, 
concomitant use of these biologicals with other immunosuppres-
sive or chemotherapeutic agents and the underlying conditions, 
as well as under-reporting (98). The experience learned from Rtx 
for autoimmune disease demonstrates that the lower the baseline 
IgM and IgG levels, the lower post-treatment IgM and IgG levels, 
the higher infection risk (96, 99), with an accumulative effect after 
repeated cycles (100).
PRACTiCAL iSSUeS iN THe PReveNTiON 
OF iNFeCTiOUS COMPLiCATiONS
vaccination
Protecting immunocompromised patients against vaccine-
preventable infectious diseases is a commonly missed opportu-
nity (101). Although there are no randomized studies showing 
that vaccination may alter infection rates or outcomes from 
acquired infections in CLL, routine vaccinations should be 
maintained in these patients before initiation of treatment 
if possible (39, 102). All live vaccines are contraindicated, 
including zoster, since severe and even fatal complications 
have been reported. Diverse studies have shown reasonable 
rates of seroprotection and seroconversion in various immu-
nocompromised hosts, including oncology patients, with very 
minimal downside (101). Conjugate vaccines have proved to 
be highly immunogenic and are to be recommended in these 
patients (46, 103).
Therefore, subunit vaccines against seasonal influenza and 
against H1N1 are broadly recommended across oncologic 
patient  populations, given the severity of the H1N1 pandemic 
and the highly severe flu impact respect to general population 
despite poor responses in CLL, and even two doses regimen 
(48, 101, 104–107).
Streptococcus pneumoniae is the commonest pathogen in 
hematological malignancy, and invasive disease is significantly 
higher in MM and more modestly in CLL and NHL. As 
discussed earlier, although vaccination of seven-valent pneu-
mococcal vaccine show protection to six of the seven antigens 
in 40% in series of CLL patients when administered early and 
prior to therapy (108), there is no data on infection prevention 
by such immunization in CLL. Despite this, it is now recom-
mended to administer both the 13-valent and the 23-valent 
vaccine (107, 109), since 58% of untreated CLL patients showed 
a response (103).
A moderate vaccination response rate of 43% against H. influ-
enzae type b (Hib) conjugate vaccine among adult and elderly 
patients with CLL has been reported (110) but will only protect 
against type b H. influenzae and not against the much more com-
mon infection by the non-encapsulated pathogen. Normal IgG1 
and IgA concentrations were associated with protection, while 
IgM, in turn, was the best predictor of a significant vaccination 
response.
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Patients receiving intensive chemo- or immunotherapy should 
be screened for hepatitis B and C infection (grade of evidence 
A1). Hepatitis B vaccine is indicated for patients with CLL who 
are negative for antibodies against HBsAg; the combined hepatitis 
A and B vaccine should be considered (111) in endemic regions. 
The HPV vaccine may be considered for all HPV-seropositive 
subjects with hematological malignancies, as these malignancies 
have been associated with high risk of second primary malignan-
cies in general (112, 113), and with HPV in particular in a recent 
study (not only skin cancer but also prostate and colon cancer 
cells were HPV DNA by PCR) (114).
Given the suboptimal immune responses to immunization 
of immunocompromised patients, the optimal timing dosing, 
use of adjuvants, and delivery method might maximize the 
immunologic benefit of vaccination in oncology patients (101). 
A potential beneficial strategy could be to vaccinate patients early 
at diagnosis, for instance at MBL stage, when better responses 
are attained than CLL (115). The same might be true for MGUS 
patients at risk of developing MM.
Prophylactic Antibiotics
The changing spectrum of infections in CLL patients on current 
therapeutic protocols mandates a newer approach to prophylaxis 
and therapy. Early recognition of patients susceptible to infec-
tion and prophylactic administration of appropriate antibiotics 
remain the first-line management for symptomatic antibody 
deficiency in CLL (9, 21, 22).
However, clinical trials are lacking (51). In patients with 
bronchiectasis, nebulized or low dose oral antibiotics, such as 
azithromycin, can reduce the incidence of recurrent infection. 
Replacement Ig should be considered if, despite AB prophylaxis, 
there are significant breakthrough bacterial infections or if bron-
chiectasis develops or progresses (51).
Anti-infective prophylaxis is recommended for patients 
receiving purine-analog and/or alemtuzumab during treatment 
and thereafter, if tolerated herpes virus (acyclovir or equivalent) 
and anti-Pneumocystis jirovecii prophylaxis (sulfamethoxazole/
trimethoprim or equivalent) (Grade of evidence IV, B) (39, 51, 
107, 116). Antivirals are given if the patient is on chemotherapy 
(FC or FCR) and thus at high risk of opportunistic viral infec-
tion. Anti HSV and HZV prophylaxis is recommended in patients 
requiring intensive and/or immunosuppressive treatment who 
are seropositive, have a low CD4 count or a history of previous 
herpes infections (51). The duration of anti-Pneumocystis and 
herpes prophylaxis is controversial.
Patients on alemtuzumab should be monitored for CMV 
reactivation (117–119). The current management is contro-
versial; some use ganciclovir (oral or IV) prophylactically if 
viremia is present, others use ganciclovir only if viral load is 
rising. CMV viremia should be measured by PCR quantitation 
at least every 2–3 weeks. Pre-emptive ganciclovir/valganciclovir 
may be used with CMV viremia or increasing viral load, for 
14–21 days until symptoms resolve and PCR tests are negative. 
Patients’ positive for HBSAg or HBCAg may require antiviral 
treatment and should be managed jointly with a specialist in 
viral hepatitis (120).
Growth Factors
The myeloid growth factor, granulocyte colony-stimulating factor 
(G-CSF) or granulocyte macrophage colony-stimulating factor 
(GM-CSF), has radically changed the approach to the prevention 
of febrile neutropenia (121–123). Their use is recommended 
for the first cycle of chemotherapy for patients with more than 
a 20% risk of febrile neutropenia or in case of poor response to 
antibiotics with persistent neutropenia should lead to the use of 
these cytokines.
Role of Prophylactic Replacement 
immunoglobulin
Given that therapy of hematological malignancies has substan-
tially changed in the last decade with the introduction of drugs 
with different modes of action, including monoclonal antibodies, 
drugs with immunomodulatory effects such as lenalidomide, and 
targeted drugs such as tyrosine kinase inhibitors, the previous 
clinical trials may not accurately represent the drawbacks and 
benefits of IVIg/SCIg now.
Current guidelines state the use of IVIg in severe hypogam-
maglobulinemia and recurrent infections (Level of evidence I, A) 
(107). The question of the correct dose of IVIg to prevent bacterial 
infections is still unresolved and is probably patient dependent 
(9, 37, 124). Much has been learnt from the management of 
patients with PID, such as the use of clinical measures and trough 
IgG levels to guide dose adjustments and the need to use higher 
replacement doses in patients with bronchiectasis (124). As a 
general guideline, maintenance of trough serum IgG in treated 
patients above 500–700 mg/dL is a reasonable goal (9).
Treatment should be reconsidered if there is no improvement 
in the frequency or severity of bacterial infections after 1  year 
(125). The choices of subcutaneous Ig and self-infusion have 
reduced costs and improved quality of life (9, 126).
The use of IVIg prophylaxis in hematopoietic stem cell 
transplantation (HSCT) for MM patients without selection by 
immunological parameters has shown beneficial results in terms 
of quality of life, but does not seem to affect CMV infection 
incidence or other infectious complications (127–129).
Expected mechanisms of action of replacement Ig therapy 
on B cell cancer include effective reduction in infections by 
pathogen neutralization, toxin inactivation and opsonization, 
and complement-mediated bactericidal effects (130). The 
potential immunomodulatory effects of Ig therapy on the setting 
of cancer are unclear (131). Ig could induce in  vivo beneficial 
immunomodulatory effects on the malignant B cell clone by 
several potential mechanisms: inducing unresponsive anergy and 
subsequent apoptosis in B cells, by inducing proapoptotic mol-
ecules expression on tumor cells or by Fas-blocking antibodies in 
IVIg (132) or through ERK phosphorilation in vitro (133); alter-
ing activation and proliferation of B cells (132, 134); inhibition of 
B cell antigen presentation (135, 136); in vitro differentiation of 
B cells and Ig secretion (137); and other immune effects [revised 
by Corbi et al. (131)].
Increases in the immunodeficiency status of CLL and other 
hematological malignancies, and growing antibiotic resistant 
pathogens in what is being called the post-antibiotic era, have 
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renewed attention in antibody therapy. In carefully selected 
patients by clinical infectious history and antibody production 
defect (9), the criteria for initiating IVIg therapy need to be reas-
sessed in the light of data of PID management to prevent lung 
damage due to ongoing subclinical infection (138, 139). In PID, 
replacement IVIg therapy is the mainstay of treatment of subjects 
with antibody failure, and it has revolutionized the lives of these 
patients (139).
Futures studies should address the question whether in CLL 
patients requiring long-standing anti-infectious combined 
protocols with antiviral, antibiotic, and antifungal treatment, 
IVIg would add a benefit, given the occurrence of pathogens’ 
antibiotic resistance, deleterious effects on microbiota and side-
effects. Also, comparison studies of the impact of IVIg versus 
antibiotics with current protocols in terms of lung involvement 
and prognosis are necessary. In the absence of specific studies, 
recommendations for IVIg replacement in hematological malig-
nancies should be based on clinical experience in PIDs and only 
in selected individual patients.
POTeNTiAL iNDiCeS TO BeTTeR SeLeCT 
PATieNTS FOR wHOM eARLY 
iNTeRveNTiON wiTH ivig MAY Be 
BeNeFiCiAL
Chronic lymphocytic leukemia is a heterogeneous disease that 
may evolve as indolent or as an aggressive malignancy. There is 
a still a lack of biological markers underlying different clinical 
presentations (57).
We propose the following aspects to be considered in order 
to improve the rational use of IVIg in indication of B-cell 
malignancy:
 1. Selection of patients for Ig replacement therapy by proven 
antibody production deficit by routine to protein and polysac-
charide immunization protocols: antibody production deficit 
is a better tool than hypogammaglobulinemia to measure 
functional dysregulation and to define those patients with 
hematological malignancy that would benefit from IVIg 
replacement therapy.
 2. Besides, timely Ig replacement therapy can prevent structural 
lung damage and progression.
 3. Immunological monitoring is important to detect patients at 
risk of severe infections or development or progression of lung 
damage.
 4. On the basis of the currently available indications, the question 
arises whether we should consider widening the IVIg indica-
tion for “hematological malignancy” with recurrent or severe 
infections and antibody production defect to other B cell malig-
nancies. This measure may avoid discrimination of patients with 
of SLL and iNHL with secondary antibody deficiency to CLL 
and similar chemotherapeutic protocols (140).
 5. It would be interesting to ascertain whether immunopheno-
typic and cytogenetic biomarkers – 17p deletion, ZAP and 
CD38 expression, and unmutated IgH-, considered as prog-
nostic predictors in terms of overall survival, are associated 
with more profound immunodeficiency.
 6. Assessment of the long-range effects in terms of infectious 
complications and of immunosuppression of novel agents 
(i.e., BCR signaling pathway inhibitors and BCL2 antagonists) 
in combined regimens for indifferent indications (first-line 
versus repeated cycles) and of CAR T cell therapy.
CONCLUSiON
As better combination regimens with monoclonal antibodies and 
new biological agents and cell therapies are being developed, a 
profound immune dysregulation in patients with CLL and other 
hematological malignancies occurs, which clearly impact on the 
clinical course of the disease. A potential beneficial strategy 
could be to vaccinate patients at MBL and MGUS stages (for 
CLL and MM, respectively) or at the time of B-cell malignancy 
diagnosis, when better antibody responses are attained. We 
have to re-emphasize the need for evaluating and monitoring 
antibody responses to adequately select patients in whom early 
intervention with prophylactic anti-infective therapy and IVIg is 
warranted. New clinical trials would be necessary to establish the 
role of IVIg in hematological malignancy during the combina-
tion front-line protocols against antibiotic prophylaxis and to 
re-evaluate the cost-effectiveness of IVIg in this new scenario.
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